Please login to the form below

Lexapro

This page shows the latest Lexapro news and features for those working in and with pharma, biotech and healthcare.

protection for Abilify and former blockbuster antidepressant Lexapro/Celexa (escitalopram).

Lundbeck and Otsuka's Rexulti set for August launch in US

which it hopes will restore growth after the loss of patent protection on US blockbuster antidepressant Lexapro/Celexa (escitalopram).
NICE backs drug to cut alcohol consumption

its top selling treatment antidepressant Cipralex/Lexapro (escitalopram oxalate).
Lundbeck still feeling effects from Cipralex patent loss

The antidepressant sales dropped another 33% in the third quarter
NICE recommends Lundbeck’s alcohol dependency drug

Lundbeck has high hopes for Selincro as it tries to overcome the impact of the loss of patent protection for its top selling treatment antidepressant Cipralex/Lexapro (escitalopram oxalate).
Lundbeck launches Brintellix in first EU market

The first EU launch of Brintellix is another important step for the Danish company as it recovers from the loss of patent protection for its antidepressant Lexapro (escitalopram oxalate), a former ... Clinical trial results suggest Brintellix is at least

More from news
Approximately 6 fully matching, plus 39 partially matching documents found.

Pharma deals during February 2014

given the loss of patent protection on Forest's best selling depression drug Lexapro and another patent cliff looming for Nameda, its Alzheimer's drug in 2015.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Senior Account Manager / Account Director - Med Comms: Great salary and benefits

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Lead Medical Copywriter, Healthcare Brand Communications, London: Excellent package

Add my company

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Tackling a formidable foe: Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Cancer care – the power of new technologies: With patient numbers set to soar, how can we make a difference?...
Redefining communications excellence: How to be heard in today’s multichannel, multistakeholder, multimedia world...